Earlier this year, when the FDA granted initial approval to Jentadueto XR and a first-line indication to Invokamet, it gave fresh momentum to an entire category of medications: single pills that combine metformin with some other treatment for type 2 diabetes (T2D). – See more at: http://www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/as-metformin-combinations-proliferate-questions-arise-about-value#sthash.jAAOQ94L.dpuf
